Literature DB >> 195265

Antibody persistence after primary immunization with trivalent oral poliovirus vaccine.

R D Krugman, G E Hardy, C Sellers, P D Parkman, J J Witte, B C Meyer, H M Meyer.   

Abstract

Five years after primary infant immunization with trivalent oral poliovirus vaccine, employing either a three-dose primary series as recommended by the U.S. Public Health Service Advisory Committee on Immunization Practices (ACIP) or a four-dose series as recommended by the Committee on Infectious Diseases of the American Academy of Pediatrics. 115 children were serologically tested for persistence of neutralizing antibodies by the microneutralization test. Of the 57 individuals immunized according to the ACIP recommendation, antibody persistence was demonstrated in 92% for type 1 poliovirus, 98% for type 2, and 84% for type 3. Of those 58 individuals originally receiving a four-dose primary infant immunization series, the persistence of antibody was 98% to type 1, 98% to type 2, and 87% to type 3. Twenty-one of 24 negative sera showed neutralizing ability when tested by a more sensitive plaque reduction test. Thus, individuals completing either immunization schedule demonstrated satisfactory persistence of neutralizing antibody to all three poliovirus types over a five-year period.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 195265

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  6 in total

1.  The periodic health examination. Canadian Task Force on the Periodic Health Examination.

Authors: 
Journal:  Can Med Assoc J       Date:  1979-11-03       Impact factor: 8.262

2.  Seroimmunity to poliovirus in Poitiers, France.

Authors:  G Agius; S Ranger; E Baillargeau; C Rouches; M Castets
Journal:  Eur J Clin Microbiol       Date:  1986-04       Impact factor: 3.267

Review 3.  The efficacy of DPT and oral poliomyelitis immunization schedules initiated from birth to 12 weeks of age.

Authors:  N Halsey; A Galazka
Journal:  Bull World Health Organ       Date:  1985       Impact factor: 9.408

4.  Sequential inactivated (IPV) and live oral (OPV) poliovirus vaccines for preventing poliomyelitis.

Authors:  Agustín Ciapponi; Ariel Bardach; Lucila Rey Ares; Demián Glujovsky; María Luisa Cafferata; Silvana Cesaroni; Aikant Bhatti
Journal:  Cochrane Database Syst Rev       Date:  2019-12-05

5.  Paralytic poliomyelitis in Italy (1981-85).

Authors:  F Novello; F Lombardi; C Amato; R Santoro; L Fiore; M E Grandolfo; P Pasquini
Journal:  Eur J Epidemiol       Date:  1987-03       Impact factor: 8.082

Review 6.  Interrupting the transmission of wild polioviruses with vaccines: immunological considerations.

Authors:  Y Ghendon; S E Robertson
Journal:  Bull World Health Organ       Date:  1994       Impact factor: 9.408

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.